Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

Rhea-AI Summary

On April 17, 2023, Daré Bioscience (NASDAQ: DARE) announced CEO Sabrina Martucci Johnson will participate in a panel discussion at the Innovations in Women’s Health Business Conference on April 20, 2023, in Boston, MA. The panel, titled ‘What’s Hot and What’s Next in Women’s Health,’ will run from 4:00-4:45 p.m. Eastern Time and features other notable panelists including Amanda Gorman and Christine Henningsgaard. This event aims to highlight innovative products reshaping women’s health care.

Daré Bioscience is dedicated to advancing women’s health through a diverse portfolio of differentiated therapies, targeting areas such as contraception, vaginal health, and menopause. The company’s first FDA-approved product, XACIATO™, is indicated for bacterial vaginosis treatment. For further details about Daré’s offerings and mission, visit their website.

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion at the Innovations in Women’s Health Business Conference, hosted by Xpectives.Health, on April 20, 2023 at Westin Copley Place, Boston, MA.

Panel:		What’s Hot and What’s Next in Women’s Health…Innovators in Women’s Health
Date:		April 20, 2023
Time:		4:00-4:45 p.m. Eastern Time
Panelists:		Amanda Gorman, PNP, Founder, Nest Collaborative Telelactation Consultation Sabrina Martucci Johnson, President and CEO, Daré Bioscience Christine Henningsgaard, CEO, Quilted Health Emily Sylvester, MS, RD, LDN, IBCLC, Founder and CEO, Mother of Fact
Details:		Women’s Health inventors, founders and innovators will share innovative products and services available currently, and what is in the Women’s Health product pipeline that will positively impact health care for women.

For additional information on the conference, please visit https://xpectives.health/womens-health/

About Daré Bioscience

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.

Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene^®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra^®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006

OR

Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Evoke Canale
jake.robison@evokegroup.com
619.849.5383

Source: Daré Bioscience, Inc.

FAQ

What is Daré Bioscience's stock symbol?

Daré Bioscience's stock symbol is DARE.

When will Sabrina Martucci Johnson speak at the Innovations in Women’s Health Business Conference?

Sabrina Martucci Johnson will speak on April 20, 2023.

What is the focus of the panel discussion at the conference?

The panel will focus on innovations and upcoming trends in women’s health.

Where is the Innovations in Women’s Health Business Conference taking place?

The conference will take place at Westin Copley Place in Boston, MA.

What time does the panel discussion on women’s health start?

The panel discussion starts at 4:00 p.m. Eastern Time.

What is XACIATO and what is its purpose?

XACIATO is Daré’s first FDA-approved product, a vaginal gel for treating bacterial vaginosis.